Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed)
Funding Amount
Not stated
Deadline
February 11, 2027
85 days left
Grant Type
Federal
Can we apply?
Check your organization against each line. Taken from the listing; confirm with the funder's guidelines.
Eligible organizations
- Public & Indian housing authorities
- Special district governments
- City & township governments
- Private colleges & universities
- Tribal governments
- Nonprofits (501(c)(3))
- County governments
- Small businesses
Geography
- Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
Overview
Accelerating Research and Development of Next Generation Malaria Vaccines Against Malaria â A Model for Mosquito-Borne Diseases
The National Institute of Allergy and Infectious Diseases (NIAID) seeks to support basic research, discovery, and/or preclinical development of highly efficacious vaccines for malaria and potentially other mosquito-borne illness. The program will encourage novel approaches to vaccine design that capitalize on recent technological innovations including structure-based immunogen design, and/or combination vaccines to reduce parasite infection and/or reduce malaria disease burden. Grant authorities that allow NIAID to forecast this opportunity are as follows: Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 2 CFR Part 200.
Details
- Agency: National Institutes of Health
- Department: Department of Health and Human Services
- Opportunity #: RFA-AI-28-024
- Instrument: grant
Eligibility
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
Focus Areas & Funding Uses
Fields of Work
- Science research
- Global health
Categories
Browse similar grants by category
Related Grants
Open grants from this funder and similar programs
Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional)
National Institutes of Health
Amount
Varies
Deadline
November 18, 2026
Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional)
National Institutes of Health
Amount
Varies
Deadline
November 18, 2026
NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)
National Institutes of Health
Amount
Varies
Deadline
November 19, 2026
Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
National Institutes of Health
Amount
Varies
Deadline
November 19, 2026
HEAL Initiative: Pain Research Enhancement Program (PREP) (R15 Clinical Trial Optional)
National Institutes of Health
Amount
Up to $375,000
Deadline
November 23, 2026
Cellular Senescence Network (SenNet): Discovery, Validation Centers (UM1 Clinical Trials Not Allowed)
National Institutes of Health
Amount
$3,400,000 total
Deadline
November 23, 2026
Ready to apply for Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed)?
Grantable helps you assess fit, draft narratives, and track deadlines — so you can submit stronger applications, faster.
You found Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed). Now let's win it.